According to the findings by the International Federation for Animal Health, 61% of animal diseases are zoonotic, meaning they have the potential to cause human pandemics. Thus, veterinary vaccines are gaining traction as an imperative implementation for protecting animal health as well as public health as they effectively mimic the naturally acquired immunity. Increasing livestock population catering to feed the colossal non-vegetarian population coupled with the adoption of companion animals by the majority of households in developing as well as developed countries is disrupting the veterinary vaccines market. Technological advancements in vaccines, increasing consciousness concerning animal health, increasing investments by government bodies and associations, and augmented demand for animal based protein has driven this arcade to reach a staggering market size of $7.5 billion as of 2018, and the demand is estimated to increment at formidable compound annual growth rate (CAGR) of 8.2% during the forecast period of 2019 to 2025.
Economic Relief by Veterinary Vaccines-
Apart from being zoonotic, animal contagious diseases have rampant tendency to ubiquitously disrupt the economic stability of livestock production. As per the Federation of American Scientists, an epidemic of mad-cow disease in England in the 1990s cost $9 billion - $14 billion as compensation to agrarians, and additional $2.4 billion from loss of export marketplaces.
As the livestock production accounts for nearly 40% of the global agricultural production value and is an integral source of nutrition for an estimated 9 billion population by 2050, veterinary vaccines market has found a major employer in this segment as animal diseases hamper efficient production and sources economic turbulence. Some of the transboundary animal diseases highly distressing the livestock sector commercial constancy are foot-and-mouth disease (FMD), H5N1 highly pathogenic avian influenza (HPAI), avian influenza (AI), lumpy skin disease (LSD), and Newcastle Disease.
After an acute analysis of the regional veterinary vaccines market share, North America was reckoned to be the dominating region securing the apex spot in terms of generating veterinary vaccines demand. This region accounts for 32% of the global veterinary vaccines market size as of 2018. The sheer affluence can be attributed to established vaccination programs and rise in ownership of pet animals. As per the National Pet Owners Survey conducted by the American Pet Products Association (APPA) 2017-2018, 68% of the U.S families own a pet with 60.2 million household housing a companion dog. The United States Department of Agriculture (USDA) Center for Veterinary Biologics controls and authorize veterinary rabies vaccines. Some of the other canine vaccines include canine distemper, canine parvovirus, infectious canine hepatitis, adenovirus-2, leptospirosis, bordatella, canine parainfluenza virus, and Lyme disease. National Association of State Public Health Veterinarians, oversees vaccination and USDA-licensed vaccines. Thus, all these factor resonates the well-established veterinary healthcare facility disrupting the North America veterinary vaccines market growth.
There are several variants of vaccines designed for different kinds of diseases, such as veterinary viral vaccines, veterinary bacterial vaccines and veterinary parasite vaccines. Among these, live viral vaccines is the most dominant type flourishing at an application CAGR of 9.0% going through 2025. Live vaccines use an attenuated form of the germ that sources an infection. Owing to its peculiarities being identical to the natural contagion that they help in preventing, such vaccines create a resilient and enduring immune response. For instance, in 2017 Merck Animal Health pioneered the INNOVAX-ND-IBD, the first live vaccine curated with biotechnology that safeguards chickens from Newcastle Disease, transmittable bursal disease, and Marek’s ailment.
Virus-like particle (VLP)-based vaccines- Some viral proteins can instinctively accumulate into biological nanoparticles, so-called ‘virus-like particles’. VLPs impersonates viral structures and are voluntarily acknowledged by the immune system, activating an enhanced immune reaction. Noticeable samples of VLP-based vaccines are some baculovirus/insect cell-expressed veterinary vaccines against Porcine circovirus 2 (PCV2), Ingelvac CircoFLEX® for example.
Modern developments in the study of virulence and pathogenicity amalgamated with operational molecular biological approaches have augmented the balanced design of vaccines, where virulence aspects have been controllably eradicated or functionally muted. This has headed to vaccines that uphold the useful properties of live vaccines while decreasing the threat for a possible reversion of virulence. A sample of this technology is a vaccine against Bovine viral diarrhoea virus (BVBD) recently introduced in the EU (Bovela).
Veterinary vaccines market is a flourishing arcade with players implementing biological and inorganic development policies to amplify their product offerings, reinforce their terrestrial spread, increase customer reach, increase substantial marketplace share and enhance veterinary vaccine development.
Some of the key players profiled in this report are Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, Bayer AG (Bayer Animal Health), Ceva Sant? Animale, Virbac, Biovac, Neogen Corporation, and ImmuCell Corporation.
December 2017, Prondil S.A., a developer and manufacturer of animal health vaccines for livestock was acquired by Merck Animal Health. This procurement aided Merck Animal Health to develop more progressive vaccines for a livestock animal in order to extend its market towards livestock sector.
The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the veterinary vaccines market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the various vaccines types in veterinary vaccines market, and their specific advantages.
The Veterinary Vaccines Market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:
• North America: The U.S., Canada, Mexico
• South America: Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, Costa Rica
• Europe: The U.K., Germany, Italy, France, The Netherlands, Belgium, Spain, Denmark
• APAC: China, Japan, Australia, South Korea, India, Taiwan, Malaysia, Hong Kong
• Middle East and Africa: Israel, South Africa, Saudi Arabia
1. Is the market for the veterinary vaccines growing? How long will it continue to grow and at what rate?
2. Which type of systems presents the major growth opportunities?
3. Is there a possibility for change in the market structure over time?
4. Are additional developments needed for the existing product or services offerings or do the existing products meet the customer demands?
5. Do the key vendors look for partnerships to expand their businesses with respect to geography or product?
6. What are the short-term, long-term, and medium-term growth drivers for the market?
7. What are the short-term, medium-term, and long-term challenges for the market?
8. What are the short-term, medium-term, and long-term opportunities for the market
9. Who are the top players/companies of the market?
10. What are the recent innovations in the market?
11. How many patents have been filed by the leading players?
12. What are the types of patents filed by the leading players?
13. What is our Vision 2030 for veterinary vaccines market?
• Give a deep-dive analysis of the key operational strategies with focus on the corporate structure, R&D strategies, localization strategies, production capabilities, and sales performance of various companies
• Provide an overview of the product portfolio, including product planning, development, and positioning
• Discuss the role of technology companies in partnerships
• Explore the regional sales activities
• Analyze the market size and giving the forecast for current and future veterinary vaccines during the forecast 2019–2025
• Analyze the competitive factors, competitors’ market shares, product capabilities, and supply chain structures.